Physician profile
Fadi Daher
NPI 1164554572
$6,076.00
in general payments reported to CMS, 2019-2025
25 companies · $954 in 2025
The $954 reported for 2025 was more than what 77% of Nephrology (Internal Medicine) providers received nationally (typical 2025 total: $311).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,016 · 2020: $491 · 2021: $751 · 2022: $923 · 2023: $913 · 2024: $1,028 · 2025: $954.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,653 · Education: $242.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,652.99 |
| Education | $241.94 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Mallinckrodt Hospital Products INC. | $935.20 | 2020-2025 | Acthar, Terlivaz |
| Fresenius USA Marketing, INC. | $884.36 | 2019-2025 | Velphoro, Velphoro |
| Astrazeneca Pharmaceuticals LP | $825.04 | 2019-2025 | Farxiga |
| Bayer Healthcare Pharmaceuticals INC. | $484.92 | 2022-2025 | |
| Otsuka America Pharmaceutical, INC. | $390.57 | 2019-2025 | Jynarque |
| Aurinia Pharma U.S., INC. | $329.04 | 2021-2024 | Lupkynis |
| Amgen INC. | $302.18 | 2019-2023 | Tavneos |
| Travere Therapeutics, INC. | $252.64 | 2022-2025 | Filspari |
| Novartis Pharmaceuticals Corporation | $240.52 | 2023-2025 | |
| Mallinckrodt Enterprises LLC | $211.54 | 2019 | |
| Vifor Pharma, INC. | $177.13 | 2019-2025 | Veltassa, Korsuva |
| Alexion Pharmaceuticals, INC. | $144.06 | 2019-2022 | |
| Ardelyx, INC. | $131.53 | 2024-2025 | Ibsrela |
| Allergan, INC. | $124.11 | 2019 | |
| Horizon Therapeutics Plc | $123.42 | 2023 | Krystexxa |
Show all 25 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Opko Pharmaceuticals, LLC | $99.97 | 2019-2025 | Rayaldee |
| Veloxis Pharmaceuticals, INC. | $95.84 | 2022 | |
| Glaxosmithkline, LLC. | $80.39 | 2021-2025 | Benlysta |
| Calliditas Therapeutics US INC. | $73.05 | 2025 | Tarpeyo |
| Akebia Therapeutics INC | $59.51 | 2019-2020 | |
| Nuwellis, INC. | $29.00 | 2020 | |
| Cormedix INC. | $27.27 | 2024 | Defencath |
| Novo Nordisk INC | $21.19 | 2024 | Wegovy |
| Boehringer Ingelheim Pharmaceuticals, INC. | $20.12 | 2025 | Jardiance |
| Ultragenyx Pharmaceutical INC. | $13.40 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Fadi Daher listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.